Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce progress in its regulatory strategy for its first commercial product, the pre-surgical triage test. Highlights Initial pre-submission meeting held with the U.S. Food & Drug Administration (FDA) where CLEO outlined its submission framework and…
Overview Cardiol Therapeutics. (NASDAQ:CRDL,TSX:CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory…
Regardless of how the gold price is doing, the top gold-mining companies are always making moves. Right now, the…
For a long time, most of the world’s lithium was produced by an oligopoly of producers often referred to…
(TheNewswire) Company now gearing up and actively enhancing its supply chain of fully integrated electrolyzers with capacities up to…
Investor Insight Horizon Minerals’ near-term cash-flow potential and its significant land package in the prolific Western Australian goldfields with…
The S&P/TSX Venture Composite Index (INDEXTSI:JX) lost 3.38 points last week to close at 570.71. Statistics Canada released its…
Experts have long warned that global overreliance on China for the production and processing of rare earth elements (REEs)…
Heritage Mining Ltd. (CSE: HML) (“Heritage ” or the “Company ”) is pleased to announce that it has closed…